Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Imaging of Cardiotoxicity in Cardiac Amyloidosis
NCT04105634Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Oct 2019
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-NOS in cardiac amyloidosis (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Measure uptake of [18F]NOS and Florbetaben in patients with AL before and ~4 months after starting standard therapy. Started Oct 2019; status: terminated.
02
Drugs
18F-NOS
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on NCT04105634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04105634.